Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImmunityBio, Inc. Director's Dealing 2018

Aug 30, 2018

31529_dirs_2018-08-29_79410ff7-1c82-4b4e-bcbf-5af4ac49a836.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2018-08-27

Reporting Person: Nelson Sonja (Chief Financial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-08-27 Stock Option (right to buy) $3.07 A 200000 Acquired 2028-08-27 Common Stock (200000) Direct

Footnotes

F1: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022.